摘要
目的对比研究乳腺癌中免疫组化法检测c-erbB2蛋白表达和荧光免疫原位杂交法(FISH)检测HER2基因扩增,并评估其临床价值。方法免疫组化染色法及FISH法分别检测42例乳腺癌组织中c-erbB2蛋白表达及HER2基因扩增状况,并进行对比分析。结果42例乳腺癌中c-erbB2蛋白表达(+++)者22例(52.38%),表达(++)者20例(47.62%);42例乳腺癌中有20例(47.62%)出现HER2基因扩增,22例(52.38%)无扩增。两种方法的检测结果差异无统计学意义(P>0.05);但二者的吻合度一般,(k=0.430,P<0.05)。结论免疫组化可以作为临床治疗是否应用赫赛汀(Herceptin)的初筛,免疫组化呈阳性或强阳性的病例有必要进一步进行HER2基因扩增的检测,来确定临床治疗是否应用Herceptin,指导化疗药物的选择及判断患者的预后。
Objective To detect the expression of c-erbB2 prolein by immunohistochemistry and HER2 gene amplification by fluorescence in situ hybridization （FISH） in breast cancer, and to evaluate their clinical significance. Methods The expression of c-erbB2 protein and HER2 gene amplification in 42 cases of breast cancer were detected by immunohistochemical staining and FISH, respectively. Results Of 42 cases,the expression of c-erbB2 protein were strongly positive in 22 cases （52.38%） and positive in 20 cases （47.62%）, and HER2 gene amplification existed in 20 cases （47.62%）. No significant difference was found in the results between these 2 methods, and the goodness of fit of these 2 methods was not very well （k =0.430, P 〈0.05）. Conclusion The immunohistochemistry can be used in initial screening of whether select Herceptin in clinical therapy or not. In the cases with positive or strongly positive expression of c-erbB2, HER2 gene amplication should be detected.
出处
《中国医科大学学报》
CAS
CSCD
北大核心
2008年第5期664-666,共3页
Journal of China Medical University
基金
卫生部科研基金资助项目(WKJ2007-3-001)
关键词
乳腺癌
受体
HER2基因
荧光原位杂交
breast cancer
receptor
HER2 gene
fluorescence in situ hybridization
